GREY:IMVIF - Post by User
Comment by
Breakthoroughon Apr 08, 2022 2:06pm
336 Views
Post# 34588644
RE:RE:RE:RE:Presentations
RE:RE:RE:RE:Presentations ORR: 29'4% (CR 11'8%, PR: 17'6%) mOS (Overall Survival): not reached. But "long-term clinical benefit has been observed in several subjects (one patient is still on treatment after 17 months)" Keytruda was approved for this population in may 2017 with: ORR of 21% (better than the 11% of quimio). NO CR's, I guess. mOS: 10'3 months (better than the 7'4 months of quimio). All this in patients who had received Keytruda before this trial (76'4 of them, includind the ones that now reached CR).